Introduction
Acute symptomatic seizures (ASS) are events occurring in a close temporal relationship with an acute central nerve system (CNS) insult that may be metabolic, toxic, structural, infectious, or inflammatory in nature. 2 The prognosis after unprovoked seizures and ASS differs with regard to risk of seizure recurrence and mortality; therefore, it is essential to define metabolic conditions when acute symptomatic seizures might occur. 7 Electrolyte abnormalities and other metabolic derangements have frequently been associated with epileptic seizures. 3 The
International League Against Epilepsy (ILAE) has suggested cut-off values for different laboratory measures of metabolic disorders when seizures should be considered as acute symptomatic rather than unprovoked events. 1 The proposed cut-off values for metabolic derangement are arbitrary and based on case reports, and there are no systematic studies except for seizures due to hyponatremia. 6 Erroneous classification of a seizure as acute symptomatic may delay the diagnosis of an underlying progressive brain disorder, and it is essential that the cut-off values be subjected to systematic evaluation. Hypoglycemia is frequently encountered in daily clinical practice. 5 We evaluated the risk of seizures at different levels of hypoglycemia in a retrospective cross-sectional study.
Materials and methods

Design and setting
The study design was a retrospective cross-sectional observational cohort study. The study was performed at Uppsala University Hospital, which is an academic care center serving a primary population of approximately 300 000 people with 59 151 patient admissions per year. Serum glucose levels are analyzed as part of routine hospital procedures and stored in the Purpose: Few studies have been dedicated to assess neurological symptoms in relations to hypoglycemia. In this study we investigated the association between different levels of hypoglycemia and the occurrence of epileptic seizures in patients without a prior diagnosis of epilepsy. Method: A retrospective cross-sectional study. Results: We identified 388 individuals from a laboratory database in Swedish regional hospital who had been found to have a glucose value of 3.5 mM between January and December 2009. Medical records were reviewed. Hypoglycemia was defined at three different categories: 0-2 mM (40 patients), 2.1-3 mM (154 patients) and 3.1-3.5 mM (194 patients).
14 patients had disturbance of consciousness including 3 with seizures. The majority of cases had coma, a generalized tonic-clonic seizure was seen only when s-glucose dropped below 2.0 mM. Two cases with focal seizure were noted, one at s-glucose 2.0 mM, and one at s-glucose 3.3 mM.
The absolute risks (95% confidence interval) for having major neurological symptoms at glucose levels of 2.0 mM were 0.25 (0.13-0.41), 0.02 (0-0.06) at 2.1-3.0 mM and 0.01 (0-0.03) at 3.1-3.5 mM. Conclusion: Coma is the most common neurological symptom related to hypoglycemia. Epileptic seizures are rare and not as common as previously assumed.
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database of the biochemical laboratory at Uppsala University Hospital. The study was approved by the central ethics committee in Sweden, and the need for informed consent was waived.
Patient and data collection
We performed a search for all patients with blood glucose values of 3.5 mM from the laboratory database between January and December 2009. The inclusion criteria were patients who had been admitted to the hospital for further evaluation. Exclusion criteria were insufficient or inaccessible medical records and a history of epilepsy or documented non-metabolic risk factors for acute symptomatic seizures (e.g., stroke, CNS infection, traumatic brain injury, anoxic encephalopathy or other active lesion in the CNS). For each case, a search was performed for the corresponding medical records. The medical records were carefully inspected for information on demographic and clinical variables including seizures or other disturbances of consciousness within 24 h of the sampling time. 2 The variables collected for the study included the following: age, gender, documented co-morbidities, seizure type and other abnormal hematologic-biochemical analyses when available (e.g., sodium, urea, creatinine, calcium, magnesium and, ammonia). The data were anonymized prior to analysis. Hypoglycemia was classified according to the following three categories according to the ILAE cut-off values: serum glucose 0-2 mM, 2.1-3 mM and 3.1-3.5 mM.
388 patients with hypoglycemia were included, 40 in the 0-2 mM and 154 in the 2.1-3 mM category. In the 3.1-3.5 mM category, 194 patients were randomly selected out of 486 patients who were within that range. In cases of multiple sampling of the same patient, we included only the lowest serum glucose level; therefore, each patient could only have one serum glucose level in the study. In cases of multiple hospital admissions during the study period, only the lowest serum glucose level was included.
Statistical analysis
The absolute risk for each serum glucose category was estimated by dividing the number of patients with hypoglycemia by the total number of exposed individuals.
The logistic analysis was performed using SAS 9.3, and the Clopper-Pearson method was used to calculate the 95% exact confidence interval.
Results
In total, 388 patients were included in the study. Fourteen patients had disturbances of consciousness including three with seizures (see Table 1 ).
Most cases were in the category of 0-2 mM glucose. The majority of cases had coma, a generalized tonic-clonic seizure was only observed when the s-glucose dropped below 2.0 mM (1.2 mM). Two cases with focal seizure were noted: one patient had an s-glucose level of 2.0 mM, and the other patient 3.3 mM.
The mean age of patients with neuroglycemic symptoms was 54 years (range 20-87 years), and the mean age of patients without neuroglycemic symptoms was 64 years (range 2-95 years).
Twelve out of fourteen patients with neurological symptoms had diabetes mellitus and were treated with insulin alone or in combination with oral antidiabetic drugs.
Co-morbidity with alcoholism, severe illness such as nephropathy and terminal prostate cancer were contributing factors in the patients with seizures.
For details on the clinical characteristics, see Table 1 . The absolute risk for developing neurological hypoglycemic symptoms, including coma and seizures was highest in the category 0-2.0 mM (0.25 CI (13-0.41)) ( Table 2. ).
The absolute risks were 0.02 CI (0-0.06) in the category 2.1-3 mM and 0.01 (0-0.03) in the category 3.1-3.5 mM. 
Discussion
This study is the first systematic attempt to evaluate the risk of acute symptomatic seizures based on different levels of hypoglycemia. An acute neuroglycopenic symptom is a direct result of brain glucose deprivation and includes cognitive impairment, behavioral changes, psychomotor abnormalities, seizures and coma. 4 Although it is recognized that hypoglycemia may cause neurological symptoms, only limited epidemiological data are available on the relationship between the incidence of seizures and hypoglycemia. In one study in an emergency department, 125 patients were identified with symptomatic hypoglycemia. The majority of the cases had impairment of consciousness, and only 9 cases with seizures were recognized. Of these, 3 had known epilepsy, and the remaining cases were related to alcoholism. 8 This is in line with our results, which indicate that coma is the dominating neurological symptom in hypoglycemia and seizures are rare manifestation. Among our patients, only one generalized tonic-clonic seizure and two focal seizures were recorded. The case with a generalized seizure was related to a glucose level below 2.0 mM, and other aggravating circumstances such as alcoholism and additional metabolic derangement may have had some impact.
From textbooks and general overviews we are taught that there are many causes of ASS and electrolytic and metabolic disorders are believed to account for 9%. 1 How many of these cases that can be attributed to hypoglycemia are not known. From this study it is not possible to estimate the incidence of seizures induced by hypoglycemia. The risk of seizures at different blood glucose levels however, seems to be low. This study was performed using a systematic unbiased approach with a large database. However, the retrospective nature of the study is an important limitation. The observations are based on a retrospective chart review, and we have not been able to confirm the accuracy of the neurological symptoms. The symptoms may also have been instigated or aggravated by co-morbidities and other metabolic disturbances. In addition, more subtle seizures may have been missed because they would have required an EEG for diagnosis. The study was performed in a single center, which may limit its generalizability. The number of cases with seizures is small, and the CIs of the estimates are wide and partially overlapping. Importantly, the analysis could provide associations, although inference regarding causality cannot be drawn.
Notwithstanding the limitations, in this study of a large number of patients with hypoglycemia, a notably low frequency of seizures was noticed. This indicates that the risk of seizures in association with low blood glucose levels seems to be low. This is a finding of potentially great clinical relevance, since seizures in the presence of hypoglycemia are often presumed to be acute symptomatic. Should our findings be validated, a more thorough work-up of patients presenting with seizures in the presence of hypoglycemia, especially at moderate levels, might be warranted. Future large prospective studies will hopefully be useful in predicting a more precise risk estimate for seizures related to hypoglycemia.
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